文章摘要
汪国玉,张蕾,邓明影,等.来氟米特治疗银屑病关节炎疗效及安全性的Meta分析[J].安徽医药,2017,21(2):319-324.
来氟米特治疗银屑病关节炎疗效及安全性的Meta分析
Meta-analysis of efficacy and safety of leflunomide in the treatment of psoriatic arthritis
投稿时间:2016-06-04  
DOI:
中文关键词: 来氟米特  银屑病关节炎  疗效  安全性  Meta分析
英文关键词: Leflunomide  Psoriatic arthritis  Efficacy  Safety  Meta analysis
基金项目:国家自然科学基金(81603339);安徽省自然科学基金(1408085MH198)
作者单位E-mail
汪国玉 安徽医科大学附属省立医院药剂科,安徽 合肥 230001
安徽医科大学临床药理研究所,安徽 合肥 230032 
 
张蕾 安徽医科大学附属省立医院药剂科,安徽 合肥 230001  
邓明影 安徽医科大学附属省立医院药剂科,安徽 合肥 230001  
史天陆 安徽医科大学附属省立医院药剂科,安徽 合肥 230001  
魏伟 安徽医科大学临床药理研究所,安徽 合肥 230032  
姜玲 安徽医科大学附属省立医院药剂科,安徽 合肥 230001
安徽医科大学临床药理研究所,安徽 合肥 230032 
ahslyyjl@126.com 
摘要点击次数: 2165
全文下载次数: 601
中文摘要:
      目的 系统评价来氟米特治疗银屑病关节炎的疗效及安全性。 方法 通过计算机检索PubMed、Sciencedirect、中国知网、维普数据库和万方数据库,检索时限均为从建库至2015年11月。纳入来氟米特为实验组治疗银屑病关节炎的随机对照试验,根据Cochrane系统评价的方法对纳入的研究进行质量评价后,用 RevMan 5.1软件进行Meta分析。 结果 共纳入7篇研究,367例病人。Meta分析结果显示:(1)疗效:来氟米特与对照组在关节压痛评分方面差异无统计学意义[SMD=0.51,95%CI(-0.22,1.25),P=0.17],在总有效率[RR=1.41,95%CI(1.18,1.69),P=0.000 2]、关节肿胀评分[SMD=0.38,95%CI(0.06,0.70),P=0.02]、血沉(ESR)[MD=13.25,95%CI(5.98,0.51),P=0.000 4]以及C-反应蛋白(CRP)[MD=3.10,95%CI(0.48,5.71),P=0.02]方面,来氟米特治疗银屑病关节炎的疗效优于对照组。(2)安全性:来氟米特组不良反应发生率与对照组之间差异无统计学意义[RR=1.33,95%CI(0.93,1.89),P=0.12]。 结论 来氟米特治疗银屑病关节炎的疗效优于甲氨蝶呤或雷公藤多苷,不良反应的发生与甲氨蝶呤或雷公藤多苷相当。
英文摘要:
      Objective To systematically evaluate the efficacy and safety ofLeflunomide in the treatment of psoriatic arthritis. MethodsThe databases such as PubMed,Sciencedirect,CNKI,VIP and Wanfang database were electronically searched for relevant studies.Randomized controlled trials using leflunomide as the experimental group to treat psoriatic arthritis were selected and evaluated by Cochrane system evaluation.Then the meta-analysis was performed using RevMan 5.1 software. Results A total of 7 articles involving 367 patients were included.The results of meta-analysis showed:(1)Efficacy:There is no significant difference in the joint tenderness score between leflunomide and the control group [SMD=0.51,5%CI(-0.22,1.25),P=0.17].The efficacy of leflunomide is better than that of the control group in the total effective rate [RR=1.41,5%CI(1.18,1.69),P=0.000 2],joint swelling score [SMD=0.38,5%CI (0.06,0.70),P=0.02],erythrocyte sedimentation rate (ESR) [MD=13.25,5%CI (5.98,0.51),P=0.000 4] and c-reactive protein (CRP) [MD=3.10,5%CI(0.48,5.71),P=0.02].(2)Safety:There is no significant difference between the leflunomide and the control group in adverse reactions [RR=1.33,5%CI (0.93,1.89),P=0.12]. Conclusion The efficacy of leflunomide is better than that of methotrexate and tripterygium glycosides in the treatment of Psoriatic Arthritis,and their adverse reaction are equivalent.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮